Grail develops Galleri, a blood-based multi-cancer early detection test intended to detect multiple cancers from a single blood draw. The company received a $110 million equity investment from Samsung affiliates to support its plans. The reported use of funds is for international expansion of Galleri and to accelerate market adoption. The article does not provide operating metrics such as revenue or user counts. No details on prior funding rounds, valuation, founding year, or company location were included in the source. The coverage focused on the capital raise and its intended use rather than operational metrics.

Total raised

$1.8B

Funding rounds

5

Latest round

Equity

Latest activity

Jun 2026